Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine.

about

IL-6 Receptor Inhibition by Tocilizumab Attenuated Expression of C5a Receptor 1 and 2 in Non-ST-Elevation Myocardial Infarction C-reactive protein during and after myocardial infarction in relation to cardiac injury and left ventricular function at follow-up

P2860

Q58746571-E88C31AA-0395-4CA7-871F-9B63BBE39BFB Q59133072-D75ED635-B11E-4053-99F0-80CAD981354E

P2860

Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine.

Item

http://www.wikidata.org/entity/Q54488428

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine.

@en

Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine.

@nl

type

Item

label

Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine.

@en

Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine.

@nl

prefLabel

Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine.

@en

Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine.

@nl

P1476

Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine

@en

P2093

Filippo Crea

http://www.w3.org/2001/XMLSchema#string

P2860

Interleukin-1 in the pathogenesis and treatment of inflammatory diseases

Monocyte heterogeneity in cardiovascular disease

Pathogenesis of acute coronary syndromes

Anti-inflammatory therapies for cardiovascular disease

Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection.

The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study

Myocardial infarction accelerates atherosclerosis.

Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study].

Interleukin-18 mediates interleukin-1-induced cardiac dysfunction.

The problem of choice: current biologic agents and future prospects in RA.

P304

2414-2416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.1093/EURHEARTJ/EHW207

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Giovanna Liuzzo

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27252447

http://www.w3.org/2001/XMLSchema#string

Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine.

about

P2860

P2860

Anti-inflammatory treatment of acute coronary syndromes: the need for precision medicine.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698